Antibody targeting CD38 enzyme shows positive impact in treating systemic sclerosis

Scleroderma is a chronic autoimmune disease of women. Over time, people living with scleroderma develop progressive and irreversible scarring. Scarring, called fibrosis, affects the lungs, heart and kidneys, leading to poor quality of life, disability and a reduced life expectancy. There is a significant unmet medical need for strategies that will slow, stop and reverse the fibrosis process.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup